0000899243-19-024510.txt : 20191001 0000899243-19-024510.hdr.sgml : 20191001 20191001194519 ACCESSION NUMBER: 0000899243-19-024510 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20191001 FILED AS OF DATE: 20191001 DATE AS OF CHANGE: 20191001 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zalevsky Jonathan CENTRAL INDEX KEY: 0001789857 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 191130533 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH STREET 2: C/O NEKTAR THERAPEUTICS CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-10-01 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001789857 Zalevsky Jonathan C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 0 1 0 0 Chief R&D Officer Common Stock 220657 D Stock Option 12.61 2019-10-01 2023-07-30 Common Stock 21875 D Stock Option 15.55 2023-12-14 Common Stock 29688 D Stock Option 15.44 2024-05-30 Common Stock 37500 D Stock Option 13.93 2024-11-14 Common Stock 46875 D Stock Option 12.24 2024-12-12 Common Stock 15500 D Stock Option 15.71 2025-03-15 Common Stock 21250 D Stock Option 18.59 2025-04-17 Common Stock 36459 D Stock Option 18.09 2025-06-14 Common Stock 77084 D Stock Option 43.07 2025-11-14 Common Stock 87500 D Stock Option 56.90 2025-12-14 Common Stock 37625 D Stock Option 36.51 2026-12-13 Common Stock 48400 D Represents 220,657 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. As of October 1, 2019, 25,000 shares subject to this stock option are vested and exercisable. The remaining 4,688 shares subject to the stock option shall vest and become exercisable in substantially equal monthly installments on the 15th day of each calendar month until December 15, 2019 based on continued service. As of October 1, 2019, 25,000 shares subject to this stock option are vested and exercisable. The remaining 12,500 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 31st day of each calendar month (or if there is no corresponding day in any such month, on the last day of such month) until May 31, 2020 based on continued service. As of October 1, 2019, 25,000 shares subject to this stock option are vested and exercisable. The remaining 21,875 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 15th day of each calendar month until November 15, 2020 based on continued service. As of October 1, 2019, 8,000 shares subject to this stock option are vested and exercisable. The remaining 7,500 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 13th day of each calendar month until December 13, 2020 based on continued service. As of October 1, 2019, 10,000 shares subject to this stock option are vested and exercisable. The remaining 11,250 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 16th day of each calendar month until March 16, 2021 based on continued service. As of October 1, 2019, 16,667 shares subject to this stock option are vested and exercisable. The remaining 19,792 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 18th day of each calendar month until April 18, 2021 based on continued service. As of October 1, 2019, 33,334 shares subject to this stock option are vested and exercisable. The remaining 43,750 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 15th day of each calendar month until June 15, 2021 based on continued service. As of October 1, 2019, 33,333 shares subject to this stock option are vested and exercisable. The remaining 54,167 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 15th day of each calendar month until November 15, 2021 based on continued service. As of October 1, 2019, 14,000 shares subject to this stock option are vested and exercisable. The remaining 23,625 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 15th day of each calendar month until December 15, 2021 based on continued service. As of October 1, 2019, 9,075 shares subject to this stock option are vested and exercisable. The remaining 39,325 shares subject to this stock option shall vest and become exercisable in substantially equal monthly installments on the 14th day of each calendar month until December 14, 2022 based on continued service. Exhibit 24.1 - Power of Attorney Mark A. Wilson, Attorney-in-Fact 2019-10-01 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

Exhibit 24.1

                               POWER OF ATTORNEY

     Know all by these presents, that the undersigned hereby authorizes each of
Gil M. Labrucherie, Senior Vice President and Chief Financial Officer of Nektar
Therapeutics (the "Company"), Mark A. Wilson, Senior Vice President and General
Counsel of the Company, and Marie Antoinette Chavez, Associate General Counsel
of the Company to execute for and on behalf of the undersigned, in the
undersigned's capacity as an executive officer of the Company, Forms 3, 4 and 5,
and any amendments thereto, and cause such form(s) to be filed with the United
States Securities and Exchange Commission pursuant to Section 16(a) of the
Securities Act of 1934, relating to the undersigned's beneficial ownership of
securities in the Company.  The undersigned hereby grants to each such attorney-
in-fact full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 27th day of September, 2019.

                            By: /s/ Jonathan Zalevsky
                                --------------------------------
                            Print Name: Jonathan Zalevsky
                                        ------------------------